Advanced type 1 diabetes therapy, developed by Poltreg, is being commercialized

Warning: Undefined array key "juiz_sps_order" in /home/users/innoventure/public_html/ on line 302

SInce December 2016, the INNOventure fund is the first institutional investor in Poltreg. Recent years have been a period of successes for the company, both in research on breakthrough therapies and in financing and commercializing the project. The company has received, among others, funding from the National Centre for Research and Development (NCBiR) and the prestigious Horizon 2020 Program, became a laureate of the first Polish edition of MIT Enterprise Forum, was transformed into a joint-stock company and attracted new investors - Venture FIZ (Lartiq group) and PAAN Capital. The type one diabetes therapy developed by Poltreg is globally the only method available to stop the development of this disease. The drug has obtained the status of ATMP (Advanced Therapy Medicinal Product), awarded by the European Medicines Agency. This drug status, recently introduced  in Polish law, is associated with the progress of science in the field of cellular and molecular biotechnology, which results in the development of advanced therapies such as gene therapy, somatic cell therapy and tissue engineering. The ATMP status allows a drug or a therapy to be treated as a so-called "hospital exemption", which means that it can already be administered to patients and offer them an individual, unique course of treatment. The therapy developed by Poltreg is already available to patients of the Gdańsk University Clinical Center.

The company's immediate development plans include the ending of the second and completing the third phase of the clinical trial aimed at type 1 diabetes therapy registration. In addition, further products are being developed - the multiple sclerosis therapy will enter the second phase of clinical trials, and the R&D phase of developing the next new generation therapy is currently underway. In addition, the company plans to develop the laboratory and increase the team. Ambitious development plans require further investments. The possibility of public offering of shares is currently under consideration. Preliminary work on the IPO is underway in cooperation with brokerage houses, and the decision on listing will be made this autumn.